Personalized Combination Protocol for Alzheimer’s Disease and MCI
If you have been diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer’s Disease we can help you fight and possibly overcome the effects of your condition. We offer a comprehensive six month lifestyle protocol that addresses all aspects of your functioning felt to be at the heart of contributing to your brain deterioration and which has been proven in a pilot study conducted at UCLA to reverse the effects of MCI and Alzheimer’s disease.
Instead of a single drug, Metabolic Enhancement for NeuroDegeneration (MEND™) applies multiple medications, supplements, and lifestyle changes in a highly personalized manner in an effort to halt and reverse mild cognitive impairment and early-stage Alzheimer’s disease. The MEND™ Protocol utilizes existing FDA approved drugs, supplements, lifestyle changes, and existing medical tests in a novel combined manner. Personalization of therapy depends upon an individual’s genome, medical test results, the influence of other medical conditions they are experiencing, existing medications, medical history, and a number of other factors.
The MEND™ Protocol is designed to address the active underlying pathways for Alzheimer’s disease including metabolic issues, toxicity, inflammation, and mitochondrial damage. When a person experiencing cognitive problems associated with Mild Cognitive Impairment (MCI) or early Alzheimer’s disease first enters the program they undergo extensive testing of blood, genetic markers, cognitive functioning, and lifestyle (sleep, nutrition, physical activity, etc.). All of the test results are then computed into a research-based algorithm, which recommends patient specific pharmacological and nonpharmacological interventional components and behavioral changes in a detailed and individualized 15 page report.
The protocol is based on research conducted by Dr. Dale Bredensen of the Mary S Easton Center for Alzheimer’s Disease Research at UCLA and the Buck Institute for Research on Aging. Results of the initial pilot study were published in Aging in September 2014 titled “Reversal of cognitive decline: A novel therapeutic program.” (Aging Sept 2014). The results of the pilot study found that people symptomatic of cognitive impairment and placed on the MEND™ Protocol showed improved cognitive function and a reduction in Alzheimer’s disease -related symptoms within 3-6 months.